Phase 2a clinic study assessing HBI-002 in Parkinson's disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 27 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Dec 2023 New trial record
20 Dec 2023 According to a Hillhurst Biopharmaceuticals media release, the company announced the completion of a financing that, together with non-dilutive sources, funds Phase 2a clinical studies in Parkinsons disease. The financing was led by Friedman Bioventure Fund with participation from new and existing investors. These funds will allow us to bring lead drug product into patients in therapeutic areas with substantial unmet medical needs, with readouts expected in 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com